NCT06304324

Brief Summary

Effect of Perineural Dexmedetomidine vs. Dexamethasone on the duration of popliteal nerve block for Anesthesia After Pediatric ankle/foot surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started May 2024

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 22, 2024

Completed
2 months until next milestone

First Posted

Study publicly available on registry

March 12, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

May 6, 2024

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2025

Completed
Last Updated

January 21, 2025

Status Verified

January 1, 2024

Enrollment Period

11 months

First QC Date

January 22, 2024

Last Update Submit

January 17, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • time to the first need of opiate following the procedure

    Time after surgery when the patient needs opiate for the first time

    within 48 hours

Secondary Outcomes (13)

  • Face, Legs, Activity, Cry, Consolability (FLACC) Behavioral Scale

    4 hours

  • Face, Legs, Activity, Cry, Consolability (FLACC) Behavioral Scale

    6 hours

  • Face, Legs, Activity, Cry, Consolability (FLACC) Behavioral Scale

    8 hours

  • Face, Legs, Activity, Cry, Consolability (FLACC) Behavioral Scale

    12 hours

  • Face, Legs, Activity, Cry, Consolability (FLACC) Behavioral Scale

    16 hours

  • +8 more secondary outcomes

Study Arms (3)

Sham Block

PLACEBO COMPARATOR

0.2% ropivacaine for popliteal nerve block

Drug: 0.9% Sodium chloride

Dexamethasone

ACTIVE COMPARATOR

0.1mg/kg dexamethasone added to 0.2% ropivacaine for popliteal nerve block

Drug: 0.1mg/kg Dexamethasone

Dexmedetomidine

ACTIVE COMPARATOR

0.5ug/kg dexmedetomidine added to 0.2% ropivacaine for popliteal nerve block

Drug: 0.05ug/kg Dexmedetomidine

Interventions

administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block

Also known as: placebo
Sham Block

administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block

Dexamethasone

administration of 0.5ml/kg of 0.2% ropivacaine with 0.05ug/kg dexmedetomidine for the popliteal nerve block

Dexmedetomidine

Eligibility Criteria

Age3 Months - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • children scheduled for foot/ankle surgery
  • body weight \> 5kg

You may not qualify if:

  • infection at the site of the regional blockade
  • coagulation disorders
  • immunodeficiency
  • ASA= or \>4
  • steroid medication in regular use

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Spine Diseases and Pediatric Orthopedics, University of Medical Sciences, Poznań, Poland

Poznan, Wielkopolska, 61-545, Poland

RECRUITING

MeSH Terms

Conditions

Ankle InjuriesDiseaseFoot InjuriesFoot Diseases

Interventions

Sodium ChlorideDexamethasoneDexmedetomidine

Condition Hierarchy (Ancestors)

Leg InjuriesWounds and InjuriesPathologic ProcessesPathological Conditions, Signs and SymptomsMusculoskeletal DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium CompoundsPregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, FluorinatedImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Tomasz Kotwicki, Prof dr hab

    Poznan University of Medical Sciences

    STUDY CHAIR

Central Study Contacts

Malgorzata Domagalska, PhD

CONTACT

Malgorzata Domalska, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 22, 2024

First Posted

March 12, 2024

Study Start

May 6, 2024

Primary Completion

March 31, 2025

Study Completion

April 30, 2025

Last Updated

January 21, 2025

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations